WuXi Biologics (Cayman) Inc.
2269
주식 순위
#991
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman)... Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
주가
$5.73
시가총액
$23.57B
변동 (1일)
-9.03%
변동 (1년)
24.25%
국가
CN
거래 WuXi Biologics (Cayman) Inc. (2269)
카테고리
Healthcare
WuXi Biologics (Cayman) Inc. (2269)의 수익
2026 기준 수익 TTM: 0
WuXi Biologics (Cayman) Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 수익 0과 동일입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
WuXi Biologics (Cayman) Inc.의 수익 기록 (2014 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2025 | $1.04B | 56.60% |
| 2024 | $662.33M | 12.33% |
| 2023 | $589.64M | -24.09% |
| 2022 | $776.72M | 23.63% |
| 2021 | $628.25M | 108.78% |
| 2020 | $300.91M | 85.98% |
| 2019 | $161.80M | 50.86% |
| 2018 | $107.25M | 129.77% |
| 2017 | $46.68M | 84.29% |
| 2016 | $25.33M | 151.48% |
| 2015 | $10.07M | 27.28% |
| 2014 | $7.91M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| - | - |
CH
|
